Dapagliflozin Shows Appropriate Safety in Real-World Type 1 Diabetes Study
In the Dapa-ON trial, the careful selection of people with T1D and the implementation of strategies to reduce the risk of DKA were associated with dapagliflozin's appropriate safety profile.